Certara – Improving Investment in Drug Development through Biosimulation
Matthew Zierhut, Vice President, Integrated Drug Development discusses case studies that exemplify the importance of model-based meta-analysis and biosimulation in early-stage drug development to improve clinical trial success.
At Certara, Dr. Matthew Zierhut advances the integration of external aggregate clinical trial data into development decisions and commercial and regulatory strategy via model-based meta-analysis (MBMA). Matt works closely with clinical development teams to ensure MBMA is leveraged for optimal impact when making the most critical decisions
Previously, Matt was at Janssen (J&J) where over the past 5+ years he has led the development of their global MBMA capability and has worked together with many clinical development teams to ensure optimal impact of MBMA into the decision making in their programs. Prior to his time at Janssen, he held positions at Pfizer and Amylin as a pharmacometrician, implementing model-informed drug development strategies across a variety of programs and therapeutic areas. He started his professional career as a business consultant at Applied Predictive Technologies, where he designed and analyzed experimental trials to provide business recommendations for multiple Fortune 500 companies.
Matt received his PhD in Bioengineering from UC Berkeley and UCSF and holds an MBA from UC Berkeley, Haas School of Business.
